PLK1 and cancer: All these findings have aroused enormous interest for targeting PLK1 in cancer and prompted the development of selective PLK1 inhibitors (Rudolph et al, 2009; Sebastian et al, 2010), including volasertib (BI6727) with a breakthrough status for leukemia and a favorable safety profile (Döhner et al, 2014).